Buy Acomplia

Generic Name: Rimonabant

Brand Names: Acomplia

On the drug ACOMPLIA

The drug Acomplia ® (Rimonabant) is approved for sale in the European Union First-in-class CB1 blocker approved for use in patients with overweight or obese in the presence of concomitant risk factors such as diabetes mellitus type 2, or dyslipidemia. Paris, France, June 21, 2006 - Sanofi-aventis announced that the European Commission has given permission to sell the drug ACOMPLIA ® (rimonabant, 20 mg / day) in all 25 European member states. The drug ACOMPLIA ®, discovered and developed by sanofi-aventis, is the first in a new class of drugs called CB1 blockers. ACOMPLIA ® is recommended in addition to diet and exercise to treat obesity (BMI ≥ 30 kg/m2) or overweight (BMI> 27 kg/m2) with associated risk factors such as diabetes mellitus type 2, or dyslipidemia. Permission to sell the drug given on a review of a large number of data on efficacy and safety, including clinical trial data RIO, which was attended by over 6000 patients worldwide, 4500 of these patients were examined during the biennium. RIO program results showed that the drug ACOMPLIA ® in tablets of 20 mg daily significantly reduces body weight and waist circumference, and levels of HbA1c and triglycerides and increases HDL cholesterol. In conclusion, the European Commission says that 50% of the observed improvement in levels of HbA1c, HDL cholesterol and triglyceride levels higher than the result expected on the basis of only one reduction vesa.1 "Permission for use of order acomplia ® in the European Union - an important news for obese and overweight, with additional cardiometabolic risk factors such as diabetes mellitus type 2, or dyslipidemia. These patients now have new treatment options," - said Jean- Francois Dehecq, President and Chief Executive Officer of sanofi-aventis. "Through our discovery, development, and now the authorization to use the drug ACOMPLIA ®, sanofi-aventis has the pelvis showed their competence and commitment to creating new drugs for use by patients and physicians." The drug ACOMPLIA ® 20 mg is designed to reduce multiple cardiometabolic risk factors in patients with obesity and overweight. Among patients for whom the drug would be particularly useful - the patients with abdominal obesity (large waist circumference), and still suffering from diabetes and / or dyslipidemia. Nearly half the adult population with an increased waist circumference (more than 102 cm or 40 inches in men and 88 cm or 35 inches for women), have at least 3 additional risk factors, all of which increase the risk of cardiometabolic disorders. General Cardiometabolic Risk - is the sum of the risks of developing diabetes type 2 and / or cardiovascular disease, it is a combination of risk factors, which can be influenced. Among the cardiometabolic risk factors include classical risk factors such as high LDL cholesterol, hypertension and hyperglycemia, as well as new risk factors closely associated with abdominal obesity (especially indraabdominalnym fat deposition), such as insulin resistance, low HDL cholesterol , high triglycerides and inflammatory markers: adiponectin and C-reactive protein. "So far we have not had the drug to affect multiple cardiometabolic risk factors that increase the likelihood of developing cardiovascular disease and diabetes type-2" - said Dr. Luc Van Gaal of Medicine, Professor of Diabetology, Metabolism and Clinical Nutrition from the hospital, University of Antwerp (Belgium), Head of Test RIO Europe. "Rimonabant - an important step forward for treatment of multiple risk factors, the totality of which causes the risk of diabetes and cardiovascular disease. This drug has the advantage over existing methods of treatment of individual risk factors, such as high blood pressure, cholesterol and diabetes" The drug ACOMPLIA ® will be available for use in the European Union in tablets of 20 mg for admission once a day. ACOMPLIA ® will be first to market with the United Kingdom in July 2006, after which the product will go to the markets of Denmark, Ireland, Germany, Finland and Norway during the second half of 2006.

Safety and tolerability

The drug ACOMPLIA ® 20 mg was tested security involving more than 6300 patients. In placebo-controlled studies the frequency of drug discontinuation due to adverse reactions was 15.7% in the group receiving ACOMPLIA ®. The most common adverse events leading to the abolition of the drug were nausea, mood changes with depressive disorders, anxiety and golovokruzhenie.1 The drug ACOMPLIA order online ® should not be administered to patients with impaired liver function or renal function, as well as untreated mental illnesses such as pronounced depressii.1

On the drug ACOMPLIA ®

Effect of the drug ACOMPLIA ® is based on a selective blockade of CB1 receptors, localized in the brain and peripheral organs and play an important role in the metabolism of fat, including adipose tissue, liver, gastrointestinal tract and the blockade of CB1 receptors myshtsah.2 drug ACOMPLIA ® reduces excessive activity of EC system (EC system) .3, 4 EC System - a newly described physiological system that includes elements such as the CB1 receptors, suggest that this system plays an important role in regulating body weight and energy balance, as well as exchange glucose and fat.

About sanofi-aventis

Sanofi-aventis - the third largest in the world and Europe's first pharmaceutical company. Due to its large-scale scientific research and development, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and New York (NYSE: SNY) stock exchanges.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Act (1995) on the back of securities. Forward-looking statements - statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations for future operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words derived from "anticipate," "anticipates," "believe," "intends," "estimate," "plans" and similar expressions. Despite the fact that the leadership of the sanofi-aventis believes that the expectations reflected in forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to risks and uncertainties that are often difficult to predict and generally beyond the control of sanofi-aventis. As a result, actual results and developments may differ materially from those implied or expressed in, or forward-looking statements. These risks and uncertainties include those discussed or identified in the public filings with uncertainties include those discussed or identified in the public filings made by sanofi-aventis to the Commission's Securities and Exchange (SEC) and the Department of Financial Markets of France (AMF), including those listed in under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis on Form 20-F for the year ended December 31, 2004 Except as otherwise required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking statements.

Due to the presence of undigested fat, it’s natural for the bowel movement to change color. It may be clear to orange or brown. These bowel changes are a natural effect of blocking the fat from being absorbed and indicates the xenical is working.

Your man can order Propecia (Finasteride) online without prescriptions now from this site.